Tag Archives: Taylor Feehley

Immunic Inc (IMUX) Gets a Buy Rating from Chardan Capital

In a report released today, Taylor Feehley from Chardan Capital reiterated a Buy rating on Immunic Inc (IMUX – Research Report), with a price target of $40. The company’s shares closed last Monday at $14.66, close to its 52-week low

Chardan Capital Reaffirms Their Buy Rating on Immunic Inc (IMUX)

In a report released today, Taylor Feehley from Chardan Capital reiterated a Buy rating on Immunic Inc (IMUX – Research Report), with a price target of $40. The company’s shares closed on Friday at $13.01, close to its 52-week low

Chardan Capital Keeps a Hold Rating on Assembly Biosciences (ASMB)

Chardan Capital analyst Taylor Feehley reiterated a Hold rating on Assembly Biosciences (ASMB – Research Report) today and set a price target of $30. The company’s shares opened today at $11.83, close to its 52-week low of $11.49. Feehley observed:

Chardan Capital Sticks to Their Hold Rating for Evelo Biosciences Inc (EVLO)

Chardan Capital analyst Taylor Feehley reiterated a Hold rating on Evelo Biosciences Inc (EVLO – Research Report) today and set a price target of $10. The company’s shares opened today at $5.69, close to its 52-week low of $5.13. According

Chardan Capital Thinks Spring Bank Pharmaceuticals Inc’s Stock is Going to Recover

Chardan Capital analyst Taylor Feehley reiterated a Buy rating on Spring Bank Pharmaceuticals Inc (SBPH – Research Report) today and set a price target of $25. The company’s shares opened today at $4.60, close to its 52-week low of $3.58.

Immunic Inc (IMUX) Receives a Buy from Chardan Capital

Immunic Inc (IMUX – Research Report) received a Buy rating and a $40 price target from Chardan Capital analyst Taylor Feehley today. Feehley wrote: “We initiate coverage of Buy rating (PT$40) based on a partly derisked yet differentiated approach to